Concert Pharmaceuticals, Inc. (CNCE) Reaches $24.98 52-Week High; Sensient Technologies (SXT)’s Sentiment Is 1.17

December 7, 2017 - By Maria Brooks

Sensient Technologies Corporation manufactures and markets colors, flavors, and fragrances in the United States and internationally. The company has market cap of $3.32 billion. The firm operates through two divisions, Flavors & Fragrances Group, and Color Group. It has a 30.79 P/E ratio. The Flavors & Fragrances Group segment develops, makes, and supplies systems products, including flavor-delivery systems, and compounded and blended products; ingredient products, such as essential oils, natural and synthetic flavors, and aroma chemicals; chili powder; paprika; chili pepper; and dehydrated vegetables comprising parsley, celery, and spinach.

The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) hit a new 52-week high and has $26.73 target or 7.00% above today’s $24.98 share price. The 7 months bullish chart indicates low risk for the $568.86 million company. The 1-year high was reported on Dec, 7 by Barchart.com. If the $26.73 price target is reached, the company will be worth $39.82M more. The stock increased 5.53% or $1.31 during the last trading session, reaching $24.98. About 125,079 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 18.70% since December 7, 2016 and is uptrending. It has outperformed by 2.00% the S&P500.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $568.86 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 6.43 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Investors sentiment increased to 1.13 in 2017 Q2. Its up 0.08, from 1.05 in 2017Q1. It improved, as 11 investors sold Concert Pharmaceuticals, Inc. shares while 21 reduced holdings. 14 funds opened positions while 22 raised stakes. 13.83 million shares or 0.29% more from 13.79 million shares in 2017Q1 were reported. Legal General Gru Public Limited Liability Corp accumulated 4,429 shares or 0% of the stock. California Employees Retirement Systems stated it has 85,000 shares. Principal Fin Inc invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 119,184 are owned by Invesco Limited. Rhenman And Prtn Asset Management Ab reported 30,099 shares. Qs Investors Lc has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Millennium Management Limited Liability Company stated it has 186,168 shares. State Of New Jersey Common Pension Fund D accumulated 40,000 shares or 0% of the stock. Senzar Asset Mgmt Limited Liability Corp owns 412,145 shares. Adage Cap Prns Lc holds 0.02% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 479,000 shares. Numeric Ltd Liability Corp holds 0.01% or 60,200 shares. Plante Moran Financial Advsrs Limited Liability has invested 0.01% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 488,285 were reported by Driehaus Mgmt Ltd Liability Corp. Bnp Paribas Arbitrage invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 434,752 were accumulated by Lyon Street Capital Limited Company.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Concert Pharmaceuticals has $32.0 highest and $20.0 lowest target. $26.50’s average target is 6.08% above currents $24.98 stock price. Concert Pharmaceuticals had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was downgraded by UBS on Monday, November 9 to “Neutral”. H.C. Wainwright maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rating on Friday, November 10. H.C. Wainwright has “Buy” rating and $21.0 target. JMP Securities maintained it with “Market Outperform” rating and $24 target in Wednesday, March 9 report. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Thursday, October 19 by Stifel Nicolaus. The rating was maintained by Roth Capital on Tuesday, September 22 with “Buy”. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Monday, November 6 by Mizuho. H.C. Wainwright maintained the stock with “Buy” rating in Friday, October 20 report. The firm has “Buy” rating given on Wednesday, August 12 by Brean Capital. Aegis Capital maintained it with “Buy” rating and $2500 target in Monday, June 12 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on March, 5. They expect $-0.58 earnings per share, down 7.41% or $0.04 from last year’s $-0.54 per share. After $-0.70 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -17.14% EPS growth.

Garrison Financial Corp holds 2.45% of its portfolio in Sensient Technologies Corporation for 52,334 shares. Tributary Capital Management Llc owns 214,242 shares or 1.52% of their US portfolio. Moreover, Lloyds Banking Group Plc has 1.39% invested in the company for 1,785 shares. The California-based Snyder Capital Management L P has invested 1.34% in the stock. Wafra Investment Advisory Group Inc Ny, a New York-based fund reported 273,517 shares.

The stock increased 0.39% or $0.3 during the last trading session, reaching $76.46. About 59,881 shares traded. Sensient Technologies Corporation (SXT) has risen 20.27% since December 7, 2016 and is uptrending. It has outperformed by 3.57% the S&P500.

Analysts await Sensient Technologies Corporation (NYSE:SXT) to report earnings on February, 8. They expect $0.84 earnings per share, up 5.00% or $0.04 from last year’s $0.8 per share. SXT’s profit will be $36.52 million for 22.76 P/E if the $0.84 EPS becomes a reality. After $0.89 actual earnings per share reported by Sensient Technologies Corporation for the previous quarter, Wall Street now forecasts -5.62% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: